

Aarti Industries

14 May 2024

RESULT UPDATE

Sector: Chemical	Rating: HOLD
CMP: Rs 669	Target Price: Rs 648

Stock Info

Sensex/ Nifty	72,776/ 22,104
Bloomberg	ARTO IN
Equity shares (mn)	363
52-wk High/Low	755/443
Face value	Rs 5
M-Cap	Rs 244bn/ USD 2.9bn
3-m Avg traded value	USD 10.8mn


Financial Snapshot (Rs mn)

Y/E March (Rs mn)	FY24	FY25E	FY26E
Net sales	70,120	87,650	1,05,180
EBITDA	9,760	15,155	18,651
PAT (adj.)	4,160	7,455	9,792
EPS (adj.) (Rs)	11.5	20.6	27.0
PE (x)	58.3	32.5	24.8
P/B (x)	4.6	3.6	3.2
EV/EBITDA (x)	28.2	18.6	15.0
RoE (%)	8.1	12.5	13.8
RoCE (%)	7.2	11.5	12.8
D/E (x)	0.6	0.6	0.5
OPM (%)	13.9	17.3	17.7
Dividend Per Share (Rs)	1.5	4.1	5.4
Dividend Yield (%)	0.2	0.6	0.8
Dividend payout (%)	13	20	20

Shareholding pattern (%)

	Dec'23	Sep'23	Jun'23
Promoter	43.6	43.6	43.7
-Pledged	2.4	-	-
FII	10.8	10.6	12.2
DII	15.9	16.2	14.9
Others	29.7	29.6	29.2

Stock Performance (1-year)



Pratik Tholiya
pratiktholiya@systematixgroup.in
+91 22 6704 8028

Kalash Jain
kalashjain@systematixgroup.in
+91 22 6704 8038

Volume and margins improve sequentially

Aarti Industries' (ARTO IN) 4Q revenue increased 7% YoY and 2% QoQ to Rs 17.7bn, (8% lower than our estimate), driven by sequential volumes uptick in the discretionary segment propelled by better demand recovery and also due to passing on of input price inflation. Soft raw material (RM) costs led to 316bps QoQ improvement in gross margin to 39.6% (-228bps YoY), more than our estimate of 36%. Other expenses increased 19% QoQ mainly on higher freight costs. EBITDA increased 13% YoY and 9% QoQ to Rs 2.8bn, but fell 4% short of our expectation. EBITDA margin expanded 80bps YoY and 95bps QoQ to 16%, overshooting our estimate of 15.3%, on a favourable product mix. APAT (Rs 1.3bn, -11% YoY, +6% QoQ) was broadly in line.

Key takeaways: Management has guided (1) 20-30% volume growth for FY25, which it believes should pick up 1Q onwards and continue every quarter; it expects volume recovery across sectors (2) FY25 EBITDA to sustain at Rs 14.5-17bn, likely to be driven by capacity ramp up and higher operating leverage, (3) FY25 capex of Rs 15-18bn, (4) Nitrotoluene and ethylation capex to be commissioned by 2QFY25, which will likely generate revenue 3QFY25 onwards, given that the company has already tied up for some of the volumes with customers, (5) FY26 EBITDA at 20-25% CAGR, driven by ramping up of Zone 4, new strategic opportunities and higher utilisation of existing capacities at Zones 1, 2 and 3. We maintain HOLD rating on ARTO, exercising caution in light of sector-wide headwinds within the specialty chemicals space. While sequential volume improvement in the discretionary segment is a positive signal, agrochemicals and pharmaceuticals still await demand normalization. We raise our FY25E/FY26E EPS by 1% each to reflect the FY24 performance. Our revised target price of Rs 648 (earlier Rs 642), valued at 24x FY26E P/E (unchanged), reflects our tempered outlook. Key risks: slower-than-expected demand recovery in discretionary products and lower offtake of value-added products (VAP).

Discretionary segment continues to improve, while non-discretionary remains under pressure: Products within ARTO's discretionary portfolio have been witnessing volume recovery for the second straight quarter in a row, while those within the non-discretionary portfolio (agrochemicals and pharmaceuticals) continue to remain soft. We expect the demand for non-discretionary products to gradually improve and contribute to volume growth in the upcoming quarters. Management expects a broad-based progressive revival in FY25.

4QFY24 volume update: 1) NCB: ~ 17,646 MT vs 18,842 MT in 4QFY23 and 19,580 MT in 3QFY24, 2) Hydrogenated products: 3,389 TPM vs 3,315 TPM in 4QFY23 and 3,644 TPM in 3QFY24, and 3) Nitro toluene: 6,675 MT vs 6,130 MT in 4QFY23 and 6,951 MT in 3QFY24. **PDA:** ~523 TPM vs 348 TPM in 4QFY23 and 481 TPM in 3QFY24.

Capex guidance: ARTO incurred a capex of Rs 12.8bn in FY24 and has guided Rs 15-18bn for FY25. It expects to commission the expanded capacities of nitrotoluene and ethylation by 2QFY25. Acid Phase 2 expansion, debottlenecking and expansion of few specialty chemicals units, greenfield projects at Zone 4 (MPP, pilot plant and chlorotoluene units), are progressing as planned.

Investors are advised to refer disclosures made at the end of the research report.

Concall KTA

- **FY25 EBITDA guidance:** Maintained at Rs 14.5–Rs 17bn.
- **Red Sea issue:** Concerns related to Red Sea resulted in freight costs and transit times increasing. Management says a higher round trip time could disrupt the global supply chain in future, likely altering global sourcing strategies.
- **Demand trends:** Demand in ARTO's regular markets is improving, driving down reliance on the non-regular ones. Major customers in the different segments are witnessing demand revival, except in agrochemicals.
- **Geographical revenue mix:** 11% North America, 6% Europe, 4% China, 3% Japan
- In FY24, its long-term contract of Rs 33bn contributed revenue of less than Rs 1bn and is expected to contribute Rs 2.5bn in FY25.
- **MMA contract:** Management expects 50-60% YoY revenue growth from this contract incrementally.
- **Tax benefit: FY24:** Negative due to deferred tax assets; **FY25:** 12-15%.
- **Gross margin fluctuation:** Favourable product mix aided sequential improvement in gross margin. The focus is on gross profit (absolute terms) and profit per kg for specific products.
- **Outlook on agrochemicals:** Demand remains under pressure.
- **Ethylation and nitrotoluene:** Primarily geared towards agrochemicals, but nitrotoluene has wider applications.
- **FY24 discretionary and non-discretionary mix: Discretionary:** ~65%, **non-discretionary:** ~35%.

Change in estimates

We have slightly raised our FY25E/FY26E revenue by 1%/0.5%, respectively, but retained our EBITDA margins for these periods. We have raised EPS by 1% each for FY25/26E. Reiterating HOLD with a revised TP of Rs 648 (Rs 642 earlier), based on 24x FY26E P/E (unchanged).

Exhibit 1: Change in estimates

	Old Estimates		New Estimates		Change (%)	
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Net Sales	78,702	95,134	79,762	95,580	1.3	0.5
EBITDA	14,920	18,515	15,155	18,651	1.6	0.7
EBITDA Margin (%)	19.0	19.5	19.0	19.5	4bp	5bp
Adjusted PAT	7,393	9,692	7,455	9,792	0.8	1.0
EPS (INR)	20.4	26.7	20.6	27.0	0.8	1.0
Target Price		642		648		1.0

Source: Company, Systematix Institutional Research

Exhibit 2: Quarterly financial statement

YE March (Rs mn)	4QFY24	4QFY23	YoY(%)	3QFY24	QoQ(%)
Net Sales	17,730	16,550	7.1	17,320	2.4
Raw material cost	10,710	9,620	11.3	11,010	(2.7)
Employees cost	1,000	1,090	(8.3)	1,030	(2.9)
Other expenses	3,190	3,330	(4.2)	2,680	19.0
Operating Expenses	14,900	14,040	6.1	14,720	1.2
% of Sales	84	85	-80bp	85	-95bp
EBITDA	2,830	2,510	12.7	2,600	8.8
EBITDA Margins (%)	16.0	15.2	80bp	15.0	95bp
Other Income	-	-	NA	80	NA
Finance Cost	590	330	78.8	540	9.3
Depreciation	980	840	16.7	970	1.0
PBT	1,260	1,340	(6.0)	1,170	7.7
Tax	(60)	(150)		(70)	
Effective Tax Rate (%)	(5)	(11)		(6)	
Reported PAT	1,320	1,490	(11.4)	1,240	6.5
NPM (%)	7	9	(156)	7	29bp
Adjusted PAT	1,320	1,490	(11.4)	1,240	6.5
No. of equity shares	363	363		363	
Adj. EPS (Rs)	3.6	4.1	(11.4)	3.4	6.5

Source: Company, Systematix Institutional Research

Exhibit 3: Key Ratios

Key Ratios (% of revenues)	4QFY24	4QFY23	YoY(%)	3QFY24	QoQ(%)
Raw Material Cost	60	58	228bp	64	-316bp
Staff Costs	6	7	-95bp	6	-31bp
Other Expenses	18	20	-213bp	15	252bp
Effective Tax rate	(5)	(11)	NA	(6)	NA
Gross Margin	39.6	41.9	-228bp	36.4	316bp
OPM	16.0	15.2	80bp	15.0	95bp
NPM	7.4	9.0	-156bp	7.2	29bp

Source: Company, Systematix Institutional Research

FINANCIALS

Profit & Loss Statement

YE: Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Net revenues	68,711	72,830	70,120	87,650	1,05,180
Revenue growth (%)	35.1	8.8	-3.7	25.2	19.8
- Op. expenses	43,654	55,300	53,960	64,606	76,929
EBITDA (Excl. OI)	17,201	10,890	9,760	15,155	18,651
EBITDA margins (%)	25.0	15.0	13.9	17.3	17.7
- Interest expenses	1,023	1,680	2,110	2,387	2,523
- Depreciation	2,464	3,100	3,780	4,397	5,085
+ Other income	10	10	80	399	478
- Tax	1,863	670	-210	1,316	1,728
Effective tax rate (%)	14	11	-5	15	15
Reported PAT	11,861	5,450	4,160	7,455	9,792
+/- Extraordinary items	-	-	-	-	-
+/- Minority interest	-	-	-	-	-
Adjusted PAT	11,861	5,450	4,160	7,455	9,792
EPS (Rs/share)	32.7	15.0	11.5	20.6	27.0

Source: Company, Systematix Institutional Research

Balance Sheet

YE: Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Share capital	1,813	1,813	1,813	1,813	1,813
Reserves & Surplus	43,350	47,390	51,090	65,026	72,860
Networth	45,163	49,203	52,903	66,838	74,672
Minority interest	10	10	10	10	10
Total Debt	28,110	31,240	34,170	39,830	38,391
Def. tax liab. (net)	-	-	-	-	-
Capital employed	73,283	80,453	87,083	1,06,678	1,13,073
Net Fixed assets	49,410	59,560	68,780	79,383	80,298
Investments	280	170	230	230	230
Net Working capital	21,853	18,723	16,773	26,009	31,180
Cash and bank balance	1,740	2,000	1,300	1,056	1,364
Capital deployed	73,283	80,453	87,083	1,06,678	1,13,073
Net debt	26,371	29,240	32,870	38,774	37,027
WC (days)	101	86	84	84	84
DE(x)	0.6	0.6	0.6	0.6	0.5

Source: Company, Systematix Institutional Research

Cash Flow

YE: Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
PAT	11,861	5,450	4,160	7,455	9,792
+ Non cash items	125	3,100	3,780	4,397	5,085
Cash profit	11,985	8,550	7,940	11,851	14,877
- Incr/(Decr) in WC	5,264	-3,131	-1,950	9,237	5,171
Operating cash flow	6,721	11,681	9,890	2,615	9,706
- Capex	2,970	13,250	13,000	15,000	6,000
Free cash flow	3,751	-1,570	-3,110	-12,385	3,706
- Dividend	544	906	540	1,491	1,958
+ Equity raised	12,871	-	-	-	-
+ Debt raised	-4,652	3,130	2,930	5,660	-1,439
- Investments	-355	-110	60	-	-
- Misc. items	14,167	504	-80	-7,972	-
Net cash flow	-2,385	261	-700	-244	309
+ Opening cash	4,124	1,740	2,000	1,300	1,056
Closing cash	1,740	2,000	1,300	1,056	1,364

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY22	FY23	FY24	FY25E	FY26E
P/E (x)	15.4	34.5	58.3	32.5	24.8
P/BV (x)	4.1	3.8	4.6	3.6	3.2
EV/EBITDA (x)	13.2	19.9	28.2	18.6	15.0
RoE (%)	27.4	10.8	8.1	12.5	13.8
RoCE (%)	20.0	9.7	7.2	11.5	12.8
Fixed Asset turnover (x)	1.2	1.2	0.9	1.0	1.0
Dividend (%)	30	50	30	82	108
Dividend yield (%)	0.3	0.5	0.2	0.6	0.8
Dividend payout (%)	5	17	13	20	20
Debtors days	65	52	47	47	47
Creditor days	21	22	30	30	30
Inventory days	56	57	66	66	66
Revenue growth (%)	35	9	-4	25	20
EBITDA growth (%)	75	-37	-10	55	23
PAT growth (%)	122	-54	-24	79	31

Source: Company, Systematix Institutional Research

Institutional Equities Team

Nikhil Khandelwal	Managing Director	+91-22-6704 8001	nikhil@systematixgroup.in
Equity Research			
Analysts	Industry Sectors	Desk-Phone	E-mail
Dhananjay Sinha	Co Head of Equities & Head of Research - Strategy & Economics	+91-22-6704 8095	dhananjaysinha@systematixgroup.in
Abhishek Mathur	FMCG	+91-22-6704 8059	abhishekmathur@systematixgroup.in
Ashish Poddar	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8039	ashishpoddar@systematixgroup.in
Himanshu Nayyar	Consumer Staples & Discretionary	+91-22-6704 8079	himanshunayyar@systematixgroup.in
Manjith Nair	Banking, Insurance	+91-22-6704 8065	manjithnair@systematixgroup.in
Pradeep Agrawal	NBFCs & Diversified Financials	+91-22-6704 8024	pradeepagrawal@systematixgroup.in
Pratik Tholiya	Specialty & Agro Chem, Fertilisers, Sugar, Textiles and Select Midcaps	+91-22-6704 8028	pratiktholiya@systematixgroup.in
Sameer Pardikar	IT & ITES	+91-22-6704 8041	sameerpardikar@systematixgroup.in
Santosh Yellapu	Capital Goods	+91-22-6704 8094	santoshyellapu@systematixgroup.in
Shweta Dikshit	Metals & Mining	+91-22-6704 8042	shwetadikshit@systematixgroup.in
Sudeep Anand	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8085	sudeepanand@systematixgroup.in
Vishal Manchanda	Pharmaceuticals and Healthcare	+91-22-6704 8064	vishalmanchanda@systematixgroup.in
Chetan Mahadik	Consumer Staples & Discretionary	+91-22-6704 8091	chetanmahadik@systematixgroup.in
Deeksha Bhardwaj	Strategy & Economics	+91-22-6704 8017	deekshabhardwaj@systematixgroup.in
Devanshi Kamdar	IT & ITES	+91-22-6704 8098	devanshikamdar@systematixgroup.in
Hinal Kothari	Metals & Mining	+91-22-6704 8076	hinalkothari@systematixgroup.in
Jennisa Popat	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8066	jennisapopat@systematixgroup.in
Kalash Jain	Midcaps	+91-22-6704 8038	kalashjain@systematixgroup.in
Krishna Zaveri	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8023	krishazaveri@systematixgroup.in
Mahek Shah	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8040	mahekshah@systematixgroup.in
Nirali Chheda	Banking, Insurance	+91-22-6704 8019	niralichheda@systematixgroup.in
Pashmi Chheda	Banking, Insurance	+91-22-6704 8063	pashmichheda@systematixgroup.in
Pravin Mule	NBFCs & Diversified Financials	+91-22-6704 8034	pravinmule@systematixgroup.in
Prathmesh Kamath	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8022	prathmeshkamath@systematixgroup.in
Purvi Mundhra	Macro-Strategy	+91-22-6704 8078	purvimundhra@systematixgroup.in
Rajesh Mudaliar	Consumer Staples & Discretionary	+91-22-6704 8084	rajeshmudaliar@systematixgroup.in
Ronak Dhruv	NBFCs & Diversified Financials	+91-22-6704 8045	ronakdhruv@systematixgroup.in
Rushank Mody	Pharmaceuticals and Healthcare	+91-22-6704 8046	rushankmody@systematixgroup.in
Swati Saboo	Midcaps	+91-22-6704 8043	swatisaboo@systematixgroup.in
Vivek Mane	Pharmaceuticals and Healthcare	+91-22-6704 8046	vivekmane@systematixgroup.in
Yogeeta Rathod	Midcaps	+91-22-6704 8081	yogeetarathod@systematixgroup.in
Equity Sales & Trading			
Name		Desk-Phone	E-mail
Vipul Sanghvi	Co Head of Equities & Head of Sales	+91-22-6704 8062	vipulsanghvi@systematixgroup.in
Jignesh Desai	Sales	+91-22-6704 8068	jigneshdesai@systematixgroup.in
Sidharth Agrawal	Sales	+91-22-6704 8090	sidharthagrawal@systematixgroup.in
Shreya Chaudhary	Sales	+91-22-6704 8033	shreyachaudhary@systematixgroup.in
Rahul Khandelwal	Sales	+91-22-6704 8003	rahul@systematixgroup.in
Chintan Shah	Sales	+91-22-6704 8061	chintanshah@systematixgroup.in
Pawan Sharma	Director and Head - Sales Trading	+91-22-6704 8067	pawansharma@systematixgroup.in
Mukesh Chaturvedi	Vice President and Co Head - Sales Trading	+91-22-6704 8074	mukeshchaturvedi@systematixgroup.in
Vinod Bhuwad	Sales Trading	+91-22-6704 8051	vinodbhuwad@systematixgroup.in
Rashmi Solanki	Sales Trading	+91-22-6704 8097	rashmisolanki@systematixgroup.in
Karan Damani	Sales Trading	+91-22-6704 8053	karandamani@systematixgroup.in
Vipul Chheda	Dealer	+91-22-6704 8087	vipulchheda@systematixgroup.in
Paras Shah	Dealer	+91-22-6704 8047	parasshah@systematixgroup.in
Rahul Singh	Dealer	+91-22-6704 8054	rahulsingh@systematixgroup.in
Niraj Singh	Dealer	+91-22-6704 8096	nirajsingh@systematixgroup.in
Corporate Access			
Mrunal Pawar	Vice President & Head Corporate Access	+91-22-6704 8088	mrunalpawar@systematixgroup.in
Darsha Hiwrale	Associate Corporate Access	+91-22-6704 8083	darshahiwrale@systematixgroup.in
Production			
Madhu Narayanan	Editor	+91-22-6704 8071	madhunarayanan@systematixgroup.in
Mrunali Pagdhare	Production	+91-22-6704 8057	mrunalip@systematixgroup.in
Vijayendra Achrekar	Production	+91-22-6704 8089	vijayendraachrekar@systematixgroup.in
Operations			
Sachin Malusare	Vice President	+91-22-6704 8055	sachinmalusare@systematixgroup.in
Jignesh Mistry	Manager	+91-22-6704 8049	jigneshmistry@systematixgroup.in
Hiren Patel	Assistant Manager	+91-22-6704 8056	hirenpatel@systematixgroup.in

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Pratik Tholiya, Kalash Jain**, hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

I. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

II. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell : grievance@systematixgroup.in

Details of Registration : CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI : ARN - 64917